These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.
    Author: Siegel YI, Korczak D, Lindner A.
    Journal: Eur Urol; 1991; 19(1):16-8. PubMed ID: 1901042.
    Abstract:
    Twenty-six patients with advanced cancer of the prostate were treated with [D-SER(BUt)6]LHRH-(1-9) nonapeptide ethylamide (buserelin). All but 6 patients evidenced signs of metastasis. Blood prolactin levels were measured prior to the initiation of treatment and during a follow-up period of 18 months. A statistically significant (p greater than 0.0005) elevation in serum prolactin levels was observed after 3 months of treatment. Serum prolactin remained elevated for a total of 6 months, after which a decline to pretreatment levels was observed. Our observation of a transient rise in prolactin levels during the chronic administration of buserelin is at variance with previously published data which reported unchanged prolactin levels during such treatment.
    [Abstract] [Full Text] [Related] [New Search]